American Journal of Life Sciences

Special Issue

Pharmacogenomics & Personalized Medicine

  • Submission Deadline: 30 November 2014
  • Status: Submission Closed
  • Lead Guest Editor: Wei Zhang
About This Special Issue
Pharmacogenomics is the study of the role of genetics in drug disposition and response. Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Such approaches promise the advent of "personalized medicine"; in which drugs and drug combinations are optimized for each individual's unique genetic makeup. It’s the future model of life science and health care. Reviews and reports by the researchers are involved in this rapidly developing area. This issue focuses on those aspects:

1. The emergence of new pharmacogenomic initiatives and their impact on R&D and regulatory strategies
2. Emerging technologies for accessing and exploiting genomic information
3. Reviews of genotyping and clinical data in particular therapeutic areas
4. Development of novel diagnostic products and strategies
Lead Guest Editor
  • Wei Zhang

    Institute of Clinical Pharmacology, Xiangya Hospital, Central south university, China

Guest Editors
  • Yan Shu

    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, United States

  • Shengying Qin

    Biophysiqe Laboratory Department of Nuclear Medicine, Faculty of Medicine, Cadi Ayyad University, Shanghai, China

Published Articles
  • Gender, but Not CYP2C19 Genotypes and CYP3A Phenotypes, is a Major Determinant of Ilaprazole Pharmacokinetic

    Shan Cao , Gan Zhou , Yao Chen , Dong Guo , Zhi-rong Tan , Lan Fan , Hai-tang Hu , Xiang-hong Qin , Hong-hao Zhou , Dong-sheng Ouyang , Wei Zhang

    Issue: Volume 3, Issue 1-4, January 2015
    Pages: 14-20
    Received: 16 September 2014
    Accepted: 24 November 2014
    Published: 27 January 2015
    DOI: 10.11648/j.ajls.s.2015030104.13
    Abstract: The purpose of the study was to assess the impact of CYP2C19 genotypes, CYP3A phenotypes and gender-related difference on the pharmacokinetics of new proton pump inhibitor ilaprazole. Twenty-four healthy Chinese volunteers (age 24.0  1.9 years) were enrolled in an open-label study stratified for gender (12 males and 12 females) and their CYP2C19 g... Show More
  • Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis

    Zhiying Luo , Xi Li , Mouze Liu , Yan Shu , Jiye Yin , Xiaoping Chen , Jianquan Luo , Xiaobing Li , Wei Zhang

    Issue: Volume 3, Issue 1-4, January 2015
    Pages: 7-13
    Received: 19 November 2014
    Accepted: 22 November 2014
    Published: 27 December 2014
    DOI: 10.11648/j.ajls.s.2015030104.12
    Abstract: Objective: Association studies on the effects of GGCX gene polymorphisms on warfarin stable dose have shown conflicting results. The aim of this study is to quantitatively summarize whether GGCX gene polymorphisms have potential roles in warfarin dose requirement. Methods: Publications were searched in PubMed, Medline and ISI Web of Knowledge and c... Show More
  • Relationship between eNOS 894G>T Polymorphism and the Antihypertensive Efficiency of Two Dihydropyridine Calcium Channel Blocker Drugs, Azelnidipine and Nitrendipine, in Chinese EH Patients

    Zhiying Luo , Fazhong He , Jianquan Luo , Wei Zhang

    Issue: Volume 3, Issue 1-4, January 2015
    Pages: 1-6
    Received: 23 October 2014
    Accepted: 25 October 2014
    Published: 24 November 2014
    DOI: 10.11648/j.ajls.s.2015030104.11
    Abstract: Background: Dihydropyridine calcium-channel blockers (dCCBs) were widely used in anithypertensive treatment. The aim of this study was to examine the effect of polymorphisms of CACNA1C, eNOS and RGS2 on the antihypertensive efficiency of dihydropyridine calcium channel blocks (dCCBs) in Chinese patients with essential hypertension (EH). Methods: A ... Show More